VRCA vs. NVO
VRCA (Verrica Pharmaceuticals Inc.) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — VRCA in Biotechnology, NVO in Drug Manufacturers - General. Over the past 5 years, VRCA returned -45.34%/yr vs 2.48%/yr for NVO. Their 0.13 correlation means their historical movements had little consistent relationship.
Performance
VRCA vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, VRCA achieves a -37.18% return, which is significantly lower than NVO's -4.23% return.
VRCA
- 1D
- -0.76%
- 1M
- -14.91%
- 6M
- -25.75%
- YTD
- -37.18%
- 1Y
- -7.45%
- 3Y*
- -54.69%
- 5Y*
- -45.34%
- 10Y*
- —
- ALL TIME*
- -36.15%
NVO
- 1D
- -8.78%
- 1M
- -6.64%
- 6M
- -18.01%
- YTD
- -4.23%
- 1Y
- 2.25%
- 3Y*
- -14.32%
- 5Y*
- 2.48%
- 10Y*
- 7.55%
- ALL TIME*
- 14.37%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $504.41M | $480.49M | $577.88M | |
| $152.18K | $167.45K | $347.74K |
VRCA vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
VRCA Verrica Pharmaceuticals Inc. | -37.18% | 18.71% | -90.44% | 166.18% | -69.98% | -20.42% | -27.56% | 94.97% | -59.25% |
NVO Novo Nordisk A/S | -4.23% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | 3.18% |
Correlation
The correlation between VRCA and NVO is 0.17, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.17 |
Correlation (3Y) Balances recent behavior with more history. | 0.15 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.15 |
Correlation (All Time) Calculated using the full available price history since Jun 15, 2018 | 0.13 |
Fundamentals
VRCA:
$55.60M
NVO:
$209.19B
VRCA:
-$1.29
NVO:
DKK 27.42
VRCA:
1.94
NVO:
4.15
VRCA:
6.93
NVO:
6.70
VRCA:
$37.16M
NVO:
DKK 327.80B
VRCA:
$33.77M
NVO:
DKK 268.30B
VRCA:
-$13.54M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VRCA vs. NVO — Risk / Return Rank
VRCA
NVO
VRCA vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Verrica Pharmaceuticals Inc. (VRCA) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VRCA | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.18 | ||
| Sortino ratioReturn per unit of downside risk | +0.16 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.06 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | -0.14 | 0.11 | -0.25 |
| Martin ratioReturn relative to average drawdown | -0.23 | 0.20 | -0.43 |
Loading charts...
Drawdowns
VRCA vs. NVO - Drawdown Comparison
The maximum VRCA drawdown since its inception was -98.39%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for VRCA and NVO.
Loading charts...
Drawdown Indicators
| VRCA | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.39% | -74.70% | -23.69% |
Max Drawdown (1Y)Largest decline over 1 year | -51.91% | -43.67% | -8.24% |
Max Drawdown (3Y)Largest decline over 3 years | -96.57% | -74.70% | -21.87% |
Max Drawdown (5Y)Largest decline over 5 years | -97.65% | -74.70% | -22.95% |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -97.43% | -65.79% | -31.64% |
Average DrawdownAverage peak-to-trough decline | -64.67% | -17.93% | -46.74% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.81% | 23.97% | +7.84% |
Volatility
VRCA vs. NVO - Volatility Comparison
Verrica Pharmaceuticals Inc. (VRCA) has a higher volatility of 18.58% compared to Novo Nordisk A/S (NVO) at 12.28%. This indicates that VRCA's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| VRCA | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.58% | 12.28% | +6.30% |
Volatility (6M)Calculated over the trailing 6-month period | 57.54% | 36.87% | +20.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 95.21% | 46.77% | +48.44% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 100.14% | 38.76% | +61.38% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 95.22% | 32.76% | +62.46% |
Dividends
VRCA vs. NVO - Dividend Comparison
VRCA has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.83%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 3.83% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
VRCA Verrica Pharmaceuticals Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
VRCA vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Verrica Pharmaceuticals Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
VRCA and NVO have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
VRCA has higher volatility (18.58%) compared to NVO (12.28%). In terms of maximum drawdown, VRCA dropped -98.39% vs NVO's -74.70%.
NVO currently has the higher Sharpe Ratio (0.10 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for VRCA and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer